Kathleen  Goin net worth and biography

Kathleen Goin Biography and Net Worth

With a positive and relentless spirit, Ms. Goin builds and coaches high-performing and successful clinical development teams.

Since 1998, Ms. Goin served many patient populations by developing drugs and devices to treat different cancers, heart disease/abnormalities, and pain conditions. As Vice President, Clinical Operations at Trevena, Inc., she shaped trial execution strategies across all programs by promoting meaningful and streamlined interactions between sites and sponsor representatives and employing modern processes for lean yet highly effective trial execution. These approaches led to helping the company start and finish three Phase III studies in just under two years. In 2017, she joined colleagues to start Clinical Works, a progressive specialty consulting firm focused on helping emerging and small biotech/pharmaceutical companies start their clinical programs and execute trials. Ms. Goin holds a Master of Science in Occupational Therapy from College Misericordia.

How do I contact Kathleen Goin?

The corporate mailing address for Goin and other Palvella Therapeutics executives is 225 Franklin Street 26th Floor, Boston MA, 02110. Palvella Therapeutics can also be reached via phone at 857-246-8998 and via email at [email protected]. Learn More on Kathleen Goin's contact information.

Has Kathleen Goin been buying or selling shares of Palvella Therapeutics?

In the last ninety days, Kathleen Goin has sold $420,004.26 of Palvella Therapeutics stock. Most recently, Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a transaction totalling $420,004.26. Learn More on Kathleen Goin's trading history.

Who are Palvella Therapeutics' active insiders?

Palvella Therapeutics' insider roster includes Kathleen Goin (COO), and George Jenkins (Director). Learn More on Palvella Therapeutics' active insiders.

Are insiders buying or selling shares of Palvella Therapeutics?

In the last twelve months, Palvella Therapeutics insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $50,325.00. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 12,906 shares worth more than $1,205,979.66. The most recent insider tranaction occured on January, 21st when COO Kathleen Goin sold 4,302 shares worth more than $420,004.26. Insiders at Palvella Therapeutics own 20.5% of the company. Learn More about insider trades at Palvella Therapeutics.

Information on this page was last updated on 1/21/2026.

Kathleen Goin Insider Trading History at Palvella Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/21/2026Sell4,302$97.63$420,004.26View SEC Filing Icon  
12/17/2025Sell4,302$96.47$415,013.94View SEC Filing Icon  
11/19/2025Sell4,302$86.23$370,961.46View SEC Filing Icon  
See Full Table

Kathleen Goin Buying and Selling Activity at Palvella Therapeutics

This chart shows Kathleen Goin's buying and selling at Palvella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palvella Therapeutics Company Overview

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $79.60
Low: $78.97
High: $81.51

50 Day Range

MA: $93.89
Low: $76.43
High: $109.07

2 Week Range

Now: $79.60
Low: $16.65
High: $114.69

Volume

19,297 shs

Average Volume

250,816 shs

Market Capitalization

$942.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A